ANXA11

Across TCGA pan-cancer cohorts, ANXA11 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ANXA11’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ANXA11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ANXA11 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, PDAC, and LSCC are the cancer types where ANXA11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANXA11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.460	<.001	11	view →
PDAC	Male	All	+0.705	<.001	9	view →
LSCC	Male	II,III,IV	−0.320	<.001	8	view →
COAD	Male	All	−0.187	<.001	7	view →
CCRCC	All	III,IV	−0.151	<.001	7	view →
LUAD	All	II,III,IV	−0.091	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ANXA11–HNSC

Open the HNSC breakdown →